Aktienanalyse zu Sol Gel Technologies Ltd (SLGL)SLGLSol Gel Technologies Ltd

Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, Sol Gel Technologies Ltd is not a strong buy. The stock is priced at $65.69, which is significantly lower than the analyst price target of $285, indicating potential upside. However, the RSI is at 32.40, suggesting the stock is oversold, and it has a forward P/E ratio of 9.34, which is attractive. The main risk is the recent financial performance, as the company reported a net loss of $3.68 million for Q2 2026, a stark contrast to a net income of $11.61 million in the same quarter last year, highlighting significant volatility in earnings.

4 analysts cover SLGL: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 50.00.